Cisapride: What can we learn from the rise and fall of a prokinetic?
Version of Record online: 26 MAY 2011
© 2011 The Author. Journal of Digestive Diseases © 2011 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
Journal of Digestive Diseases
Volume 12, Issue 3, pages 147–156, June 2011
How to Cite
QUIGLEY, E. M. (2011), Cisapride: What can we learn from the rise and fall of a prokinetic?. Journal of Digestive Diseases, 12: 147–156. doi: 10.1111/j.1751-2980.2011.00491.x
- Issue online: 26 MAY 2011
- Version of Record online: 26 MAY 2011
- Accepted manuscript online: 22 MAR 2011 06:39AM EST
- gastroesophageal reflux;
- gastrointestinal motility;
Cisapride, the prototype serotonergic agent, evolved from a body of research that defined the key roles of serotonergic receptors in gastrointestinal motor and sensory function. Impressed by its in vitro properties and encouraged by clinical trial data, cisapride became the drug of choice for the treatment of a wide range of motility disorders and clinicians appeared impressed by its efficacy and comfortable with its side-effect profile. Once serious cardiac events began to be reported in association with cisapride therapy, dark clouds rapidly gathered and soon enveloped the drug, leading to its widespread withdrawal from markets. What lessons can we learn from the story of cisapride? How can its brief but spectacular rise and equally sensational demise inform the development of new drugs which are so sorely needed in the management of motility and functional gastrointestinal disorders? This review explores the background to the development of cisapride, its history in clinical trials and the experience with adverse events and, in so doing, attempts to identify lessons for the future in the therapeutics of enteric neuromodulatory drugs.